JP2022519007A - 脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン - Google Patents

脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン Download PDF

Info

Publication number
JP2022519007A
JP2022519007A JP2021534126A JP2021534126A JP2022519007A JP 2022519007 A JP2022519007 A JP 2022519007A JP 2021534126 A JP2021534126 A JP 2021534126A JP 2021534126 A JP2021534126 A JP 2021534126A JP 2022519007 A JP2022519007 A JP 2022519007A
Authority
JP
Japan
Prior art keywords
patient
baseline
patients
score
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021534126A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519007A5 (enExample
Inventor
ユハ－マッティ・サヴォラ
マーク・フォレスト・ゴードン
フランク・シュナイダー
Original Assignee
オースペックス ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オースペックス ファーマシューティカルズ インコーポレイテッド filed Critical オースペックス ファーマシューティカルズ インコーポレイテッド
Publication of JP2022519007A publication Critical patent/JP2022519007A/ja
Publication of JP2022519007A5 publication Critical patent/JP2022519007A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021534126A 2018-12-13 2019-12-13 脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン Pending JP2022519007A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862779232P 2018-12-13 2018-12-13
US62/779,232 2018-12-13
US201962801450P 2019-02-05 2019-02-05
US62/801,450 2019-02-05
PCT/US2019/066150 WO2020123900A1 (en) 2018-12-13 2019-12-13 Deutetrabenazine for the treatment of dyskinesia in cerebral palsy

Publications (2)

Publication Number Publication Date
JP2022519007A true JP2022519007A (ja) 2022-03-18
JP2022519007A5 JP2022519007A5 (enExample) 2022-12-22

Family

ID=69173404

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021534126A Pending JP2022519007A (ja) 2018-12-13 2019-12-13 脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン

Country Status (15)

Country Link
US (3) US11324732B2 (enExample)
EP (1) EP3893876A1 (enExample)
JP (1) JP2022519007A (enExample)
KR (1) KR20210114946A (enExample)
CN (1) CN113395966A (enExample)
AU (1) AU2019395250A1 (enExample)
BR (1) BR112021011386A2 (enExample)
CA (1) CA3123393A1 (enExample)
CL (1) CL2021001554A1 (enExample)
IL (1) IL283920A (enExample)
MX (1) MX2021007063A (enExample)
SG (1) SG11202106344SA (enExample)
TW (1) TWI784220B (enExample)
WO (1) WO2020123900A1 (enExample)
ZA (1) ZA202104786B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210114946A (ko) * 2018-12-13 2021-09-24 오스펙스 파마슈티칼스, 인코포레이티드 뇌성마비에서의 운동이상증의 치료를 위한 듀테트라베나진
BR112023021257A2 (pt) * 2021-04-15 2023-12-12 Neurocrine Biosciences Inc Métodos para a administração combinada de deutetrabenzina e um cyp2d6
WO2022221551A1 (en) * 2021-04-15 2022-10-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
WO2024090922A1 (ko) 2022-10-24 2024-05-02 주식회사 디자인셀 줄기세포 배양액 및 상기로부터 분리된 세포외소포를 유효성분으로 포함하는 뇌신경계 질환의 예방 또는 치료용 약학적 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018507248A (ja) * 2015-03-06 2018-03-15 オースペックス ファーマシューティカルズ インコーポレイテッド 異常不随意運動障害の処置のための方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2972242A1 (en) * 2008-09-18 2010-04-22 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
AU2015200243B2 (en) * 2009-06-24 2016-09-29 Egalet Ltd Controlled release formulations
EP3351247A1 (en) * 2010-06-01 2018-07-25 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
EP4345100A3 (en) 2012-09-18 2024-04-10 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
PE20191819A1 (es) 2017-03-15 2019-12-27 Auspex Pharmaceuticals Inc Analogos de deutetrabenazina, su preparacion y uso
KR20210114946A (ko) * 2018-12-13 2021-09-24 오스펙스 파마슈티칼스, 인코포레이티드 뇌성마비에서의 운동이상증의 치료를 위한 듀테트라베나진

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018507248A (ja) * 2015-03-06 2018-03-15 オースペックス ファーマシューティカルズ インコーポレイテッド 異常不随意運動障害の処置のための方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DEV. MED. CHILD NEUROL., vol. 59, JPN6024032760, 2017, pages 786 - 795, ISSN: 0005512149 *
MOV. DISORD., vol. 33, no. 1, JPN6024032761, June 2018 (2018-06-01), pages 92 - 93, ISSN: 0005512150 *
MOVEMENT DISORDERS, vol. 21, no. 11, JPN6023048261, 2006, pages 1966 - 1972, ISSN: 0005512153 *
NEUROLOGY, vol. Vol.82 No.10_suppl., JPN6024032762, 2014, pages 7 - 084, ISSN: 0005512151 *
厚生労働省, 重篤副作用疾患別対応マニュアル ジスキネジア, JPN6024032763, 2009, pages 5 - 6, ISSN: 0005512152 *

Also Published As

Publication number Publication date
US20200188371A1 (en) 2020-06-18
US20220409597A1 (en) 2022-12-29
CL2021001554A1 (es) 2022-02-11
WO2020123900A1 (en) 2020-06-18
EP3893876A1 (en) 2021-10-20
ZA202104786B (en) 2023-12-20
US20240082225A1 (en) 2024-03-14
CA3123393A1 (en) 2020-06-18
CN113395966A (zh) 2021-09-14
US11324732B2 (en) 2022-05-10
IL283920A (en) 2021-07-29
AU2019395250A1 (en) 2021-07-29
TWI784220B (zh) 2022-11-21
MX2021007063A (es) 2021-12-10
TW202034917A (zh) 2020-10-01
BR112021011386A2 (pt) 2021-08-31
SG11202106344SA (en) 2021-07-29
KR20210114946A (ko) 2021-09-24

Similar Documents

Publication Publication Date Title
US20250302851A1 (en) Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
Riddle et al. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial
Connor et al. Neuroleptic-related dyskinesias in children and adolescents
JP2022519007A (ja) 脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン
JP2026050474A (ja) Ｎｍｄａ拮抗薬の副作用の低減
US20250000881A1 (en) Treatment of treatment resistant depression with psilocybin
JP2022514510A (ja) うつ病の治療方法
KR20210153059A (ko) 중수소화 덱스트로메토르판 및 퀴니딘을 사용하는 정신분열병의 음성 증상의 치료 방법
Chen et al. Study of Feasibility and Safety of Higher‐Dose Dexmedetomidine in Special Outpatient Examination of Pediatric Ophthalmology
JP2025500844A (ja) 治療抵抗性うつ病の治療に使用するためのサイロシビン及び補助的セロトニン再取り込み阻害剤
JP2024517937A (ja) Ｎｍｄａ受容体拮抗薬の副作用の低減
CN119654149A (zh) 用于在治疗抑郁障碍中使用的奥法地尔的皮下施用和给药方法
EA044015B1 (ru) Дейтетрабеназин для лечения дискинезии при церебральном параличе
Ferrin et al. Using antipsychotic medication for the treatment of schizophrenia in children and adolescents
US20250375417A1 (en) Orexin receptor 2 (ox2r) agonist for use in narcolepsy type 1 (nt1)
Rajab et al. The use of chloral hydrate sedation in pediatric strabismus outpatient clinic
Pearson et al. Psychopharmacology: Issues in prescribing psychiatric medication to children and adolescents
Ghaziuddin et al. A practical guide to using ECT in minors
WO2025257799A1 (en) Methods of treating dravet syndrome
Weis Analysis of Pre-procedural Intranasal Anxiolytic Use in the Emergency Treatment of Pediatric Laceration Repair
WO2025255215A1 (en) Methods and compositions for treating sleep apnea
WO2025145241A1 (en) Treatment of gut-brain interaction disorders
HK40060751A (en) Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
Gutkovich et al. Medication treatment of bipolar disorder in developmentally disabled children and adolescents
ORLEANS Population-level rate of SUDEP may have decreased

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231127

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240527

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241226